Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies.
Delivery of monoclonal antibodies to solid tumors is a vexing problem that must be solved if these antibodies are to realize their promise in therapy. Such success as has been achieved with monoclonal antibodies is attributable to the local hyperpermeability of the tumor vasculature, a property that favors antibody extravasation at tumor sites and that is mediated by a tumor-secreted vascular permeability factor. However, leaky tumor blood vessels are generally some distance removed from target tumor cells, separated by stroma and by other tumor cells that together represent significant barriers to penetration by extravasated monoclonal antibodies. For this reason, alternative approaches may be attractive. These include the use of antibody-linked cytotoxins, which are able to kill tumor cells without immediate contact, and direction of antibodies against nontumor cell targets, for example, antigens unique to the tumor vascular endothelium or to tumor stroma.
Dvorak
H F
HF
Department of Pathology, Beth Israel Hospital, Boston, Massachusetts.
Nagy
J A
JA
Dvorak
A M
AM
D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000912:Antibodies, Neoplasm / Q000493:pharmacokinetics / Q000627:therapeutic use; D002199:Capillary Permeability; D004730:Endothelium, Vascular / Q000187:drug effects; D005110:Extracellular Space / Q000276:immunology / Q000378:metabolism; D006801:Humans; D000922:Immunotoxins / Q000493:pharmacokinetics / Q000627:therapeutic use; D007365:Intercellular Junctions / Q000648:ultrastructure; D009369:Neoplasms / Q000098:blood supply / Q000473:pathology / Q000628:therapy*; D009389:Neovascularization, Pathologic; D011868:Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000922:Immunotoxins; D011868:Radioisotopes